A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD)

NCT05276076 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Graft Versus Host Disease

Interventions

BIOLOGICAL: VM-001 1X10^6 cells/kg
BIOLOGICAL: VM-001 3X10^6 cells/kg
BIOLOGICAL: VM-001 5X10^6 cells/kg
BIOLOGICAL: VM-001 1X10^6 cells/kg two dose
BIOLOGICAL: VM-001 1X10^6 cells/kg four dose

Sponsor

ViGenCell Inc.